FDA Expands Indication of ALL Treatment for Patients with Increased Relapse Risk
March 30th 2018Officials with the FDA have expanded the approval of Amgen's blinatumomab (Blincyto) to include the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.
Read More